u/fasting_insulin_f

that is a big move on a small weight change and it is a much more interesting data point than the 9kg.

Retitled — the original quoted an obesity endpoint as a glycaemic one.

The order things move in, since nobody explains it and it worries people.

Postprandial excursions generally respond earliest. Variability tends to narrow before the average does, which is visible on a sensor and invisible on a lab result. Fasting glucose is often the laggard, and A1c — being a three-month average — is the last thing to reflect anything.

So a month in which the sensor looks better and the fasting number has not moved is the ordinary sequence, not a contradiction. Knowing that in advance would have saved me a quarter of unnecessary worry, which is why it is worth writing down.

Your ordering is not surprising if you think of insulin as the mediator rather than weight. Insulin sensitivity improves early — well before meaningful fat loss — and hyperinsulinaemia is a direct driver of ovarian androgen production and of SHBG suppression.

So "weight loss improved my PCOS" may be the wrong causal story in a lot of cases. "Improved insulin signalling improved both" fits the timelines better.

HOMA-IR is crude and free. If you have fasting insulin and glucose from month zero you can check whether that fits your own data.

Not quite.

Agreed, and for anyone finding this later: that is the normal experience, not a warning sign.

hypoglycaemia risk depends far more on what else you take

log what you did, not what you meant to do

Identifying details redacted from the exported report above.

daily dosing changes adherence in both directions

Kept every form and reference number. When they had no record of a submission, I did.

Disagree with daily weighing. You are logging fluid, and the emotional cost is real for very little information.

Identifying details redacted from the exported report above.

Special authorization is a documented exception process with published criteria. Applications that answer those criteria explicitly, point by point, fare better than general clinical narratives.

Compared milligram figures across two completely different molecule classes in a comment. Deserved the correction.

I would not draw a trend line through that.

Agreed — and the payoff genuinely arrives in month six, not week two.

Retitled — the original quoted an obesity endpoint as a glycaemic one.

Quantity limits restrict how much may be dispensed in a period even where coverage exists. They are a distinct barrier and require a distinct request.

Push back: one sensor reading is not a data point worth acting on, especially in the first day of wear.

Agreed, and the glucose-dependence point is the reason the risk profile reads the way it does.

Careful — that is a dosing recommendation dressed as an anecdote, and this board removes those.

The order things move in, since nobody explains it and it worries people.

Postprandial excursions generally respond earliest. Variability tends to narrow before the average does, which is visible on a sensor and invisible on a lab result. Fasting glucose is often the laggard, and A1c — being a three-month average — is the last thing to reflect anything.

So a month in which the sensor looks better and the fasting number has not moved is the ordinary sequence, not a contradiction. Knowing that in advance would have saved me a quarter of unnecessary worry, which is why it is worth writing down.

Retitled — the original quoted an obesity endpoint as a glycaemic one.

This. The absence of food and water timing restrictions is the practical difference people will actually notice.

Left up. It distinguishes the sensor data from the lab result, which most posts here do not.

This. Ask the basic question; the answers are what make the board searchable for the next person.

That is area percent from a certificate, not the amount of peptide in the vial. Two different numbers and a very common mix-up.

Agreed, and it is why the oral peptide comparison keeps misleading people.

mateusz_mensah is right that milligram comparisons across classes tell you nothing.

That template is elaborate enough that you will stop using it by week ten. Mine was.

sensor accuracy varies and the first day of a sensor is the worst

I confused two very similar words on my first order and asked here, expecting to be mocked. Three people explained it properly instead.

Health Canada approval is not coverage

Have you asked the pharmacist to check?

What did the denial actually say?

Small correction, said kindly: those are two different products with similar names, and the difference matters for a multi-draw vial.

Which programme and which readout are you quoting?

Annotated the fortnight I changed training. Without that note the numbers around it would look like a mystery.

Pointing this at whoever manages your diabetes. We compare experiences here; we do not adjust regimens.

Reconstructed six weeks from memory once and later found receipts that contradicted my own log.

intent_to_treat is right about blanks. Silent gaps make the series lie.

ask the dumb question, three other people are searching for it

Left up. It distinguishes the sensor data from the lab result, which most posts here do not.

Identifying details redacted from the exported report above.